Parallel evolution of drug resistance in HIV: Failure of nonsynonymous/synonymous substitution rate ratio to detect selection

Molecular Biology and Evolution

Volumn 16, Issue 3, 1999, Pages 372-382

  Crandall, Keith A ^a   Kelsey, Chris R ^b   Imamichi, Hiromi ^b   Lane, H Clifford ^b   Salzman, Norman P ^b  

^a BRIGHAM YOUNG UNIVERSITY   (United States)

^b NONE

Author keywords

Convergent evolution; Drug resistance; Drug therapy; Human immunodeficiency virus; Parallel evolution; Phylogeny

Indexed keywords

INDINAVIR; INTERLEUKIN 2;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; MUTATION RATE; NATURAL SELECTION; NUCLEOTIDE SEQUENCE; PHYLOGENY; SEQUENCE ANALYSIS; VIRUS LOAD;

EID: 0033028201     PISSN: 07374038     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.molbev.a026118     Document Type: Article

References (49)

1. AGAPOW, P. 1997. Conserve. 3.0.1. LaTrobe University, Melbourne, Australia.
2. BORMAN, A. M., S. PAULOUS, and F. CLAVEL. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77:419-426.
3. BULL, J. J., M. R. BADGETT, H. A. WICHMAN, J. P. HUELSENBECK, D. M. HILLIS, A. GULATI, C. HO, and I. J. MOLINEUX. 1997. Exceptional convergent evolution in a virus. Genetics 147:1497-1507.
4. CHUN, T.-W., L. CARRUTH, D. FINZI et al. (15 co-authors). 1997a. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
5. CHUN, T.-W., L. STUYVER, S. B. MIZELL, L. A. EHLER, J. M. MICAN, M. BASELER, A. L. LLOYD, M. A. NOWAK, and A. S. FAUCI. 1997b. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94:13193-13197.
6. CRANDALL, K. A. 1994. Intraspecific cladogram estimation: accuracy at higher levels of divergence. Syst. Biol. 43:222-235.
7. _. 1996. Multiple interspecies transmissions of human and simian T-cell leukemia/lymphoma virus type I sequences. Mol. Biol. Evol. 13:115-131.
8. CRANDALL, K. A., and A. R. TEMPLETON. 1999. Statistical approaches to detecting recombination. In K. A. CRANDALL, ed. Evolution of HIV. Johns Hopkins University Press, Baltimore, Md. (in press).
9. CROZIER, R. H. 1992. Genetic diversity and the agony of choice. Biol. Conserv. 61:11-15.
10. CROZIER, R. H., and R. M. KUSMIERSKI. 1994. Genetic distances and the setting of conservation priorities. Pp. 227-237 in V. LOESCHCKE, J. TOMIUK, and S. K. JAIM, eds. Conservation genetics. Birkhauser Verlag, Basel.
11. CUNNINGHAM, C. W., K. JENG, J. HUSTI, M. BADGETT, I. J. MOLINEUX, D. M. HILLIS, and J. J. BULL. 1997. Parallel molecular evolution of deletions and nonsense mutations in bacteriophage T7. Mol. Biol. Evol. 14:113-116.
12. DEWAR, R. L., H. C. HIGHBARGER, M. D. SARMIENTO, J. A. TODD, M. B. VASUDEVACHARI, R. T. DAVEY, J. A. KOVACS, N. P. SALZMAN, H. C. LANE, and M. S. URDEA. 1994. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J. Infect. Dis. 170:1172-1179.
13. DOOLITTLE, R. F. 1994. Convergent evolution: the need to be explicit. Trends Biochem. Sci. 19:15-18.
14. FELSENSTEIN, J. 1985. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39:783-791.
15. _. 1992. Estimating effective population size from samples of sequences: inefficiency of pairwise and segregating sites as compared to phylogenetic estimates. Genet. Res. Camb. 59:139-147.
16. FINZI, D., M. HERMANKOVA, T. PIERSON et al. (12 co-authors). 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
17. GOLDMAN, N., and Z. YANG. 1994. A codon-based model of nucleotide substitution for protein-coding DNA sequences. Mol. Biol. Evol. 11:725-736.
18. HOLMES, E. C., L. Q. ZHANG, P. SIMMONDS, C. A. LUDLAM, and A. J. LEIGH BROWN. 1992. Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. Proc. Natl. Acad. Sci. USA 89:4835-4839.
19. HUELSENBECK, J. P., and K. A. CRANDALL. 1997 Phylogeny estimation and hypothesis testing using maximum likelihood. Annu. Rev. Ecol. Syst. 28:437-466.
20. HUGHES, A. L., and M. NEI. 1988. Pattern of nucleotide substitution at major histocompatibility complex class I loci reveals overdominant selection. Nature 335:167-170.
21. KELLAM, P., and B. A. LARDER. 1995. Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J. Virol. 69:669-674.
22. KORBER, B. T. M., G. LEARN, J. I. MULLINS, B. H. HAHN, and S. WOLINSKY. 1995. Protecting HIV databases. Nature 378: 242-243.
23. KOZAL, M. J., N. SHAH, N. SHEN et al. (11 co-authors). 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med. 2:753-759.
24. KUHNER, M. K., J. YAMATO, and J. FELSENSTEIN. 1995. Estimating effective population size and mutation rate from sequence data using Metropolis-Hastings sampling. Genetics 140:1421-1430.
25. KUMAR, S., K. TAMURA, and M. NEI. 1993. MEGA: molecular evolutionary genetics analysis V 1.01. Pennsylvania State University, University Park.
26. LECH, W. J., G. WANG, Y. L. YANG, Y. CHEE, K. DORMAN, D. MCCRAE, L. C. LAZZERONI, J. W. ERICKSON, J. S. SINSHEIMER, and A. H. KAPLAN. 1996. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:2038-2043.
27. LI, W.-H. 1997. Molecular evolution. Sinauer Associates, Inc., Sunderland, Mass.
28. MESSIER, W., and C.-B. STEWART. 1997. Episodic adaptive evolution of primate lysozymes. Nature 385:151-154.
29. MIYATA, T., and T. YASUNAGA. 1980. Molecular evolution of mRNA: a method for estimating evolutionary rates of synonymous and amino acid substitution from homologous nucleotide sequences and its application. J. Mol. Evol. 16:23-36.
30. MOLLA, A., M. KORNEYEVA, Q. GAO et al. (17 co-authors). 1996. Ordered accumulation of mutations in HIV protease confer resistance to ritonavir. Nature Med. 2:760-766.
31. MUSE, S. V. 1996. Estimating synonymous and nonsynonymous substitution rates. Mol. Biol. Evol. 13:105-114.
32. MUSE, S. V., and B. S. GAUT. 1994. A likelihood approach for comparing synonymous and nonsynonymous nucleotide substitution rates, with application to the chloroplast genome. Mol. Biol. Evol. 11:715-724.
33. NEI, M., and T. GOJOBORI. 1986. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol. 3:418-426.
34. NIELSEN, R., and Z. YANG. 1998. Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 148:929-936.
35. PERELSON, A. S., P. ESSUNGER, Y. CAO, M. VESANEN, A. HURLEY, K. SAKSELA, M. MARKOWITZ, and D. D. Ho. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191.
36. POSADA, D., and K. A. CRANDALL. 1998. Modeltest: testing the model of DNA substitution. Bioinformatics (in press).
37. SAITOU, N., and M. NEI. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.
38. SCHINAZI, R. F., B. A. LARDER, and J. W. MELLORS. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News 5:129-142.
39. SHARP, P. M. 1997. In search of molecular darwinism. Nature 385:111-112.
40. STRUNNIKOVA, N., S. C. RAY, R. A. LIVINGSTON, E. RUBALCABA, and R. P. VISCIDI. 1995. Convergent evolution within the V3 loop domain of human immunodeficiency virus type 1 in association with disease progression. J. Virol. 69:7548-7558.
41. SWOFFORD, D. L. 1998. PAUP* phylogenetic analysis using parsimony and other methods. 4.0.0beta. Sinauer Associates, Sunderland, Mass.
42. TEMPLETON, A. R., K. A. CRANDALL, and C. F. SING. 1992. A cladistic analysis of phenotypic associations with haplotypes inferred from restriction endonuclease mapping and DNA sequence data. III. Cladogram estimation. Genetics 132:619-633.
43. VACCA, J. P., B. D. DORSEY, W. A. SCHLEIF et al. (23 co-authors). 1994. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA 91:4096-4100.
44. WAIN-HOBSON, S. 1997. Down or out in blood and lymph? Nature 387:123-124.
45. WEISBLUM, B. 1995. Erythromycin resistance by ribosome modification. Agents Chemother. 39:577-585.
46. WOLFRAM, S. 1991. Mathematica. Addison-Wesley, Redwood City, Calif.
47. WONG, J. K., M. HEZAREH, H. F. GUNTHARD, D. V. HAVLIR, C. C. IGNACIO, C. A. SPINA, and D. D. RICHMAN. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1295.
48. YANG, Z. 1998. Likelihood ratio tests for detecting positive selection and application to primate lysozyme evolution. Mol. Biol. Evol. 15:568-573.
49. ZHANG, Y.-M., H. IMAMICHI, T. IMAMICHI, H. C. LANE, J. FALLOON, M. B. VASUDEVACHARI, and N. P. SALZMAN. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and its gag substrate cleavage site. J. Virol. 71:6662-6670.